Saracatinib (AZD0530)

Name: Saracatinib (AZD0530)
Brand: Selleck Chemicals
SKU: S1006
Rating: 5 (217 reviews)

For research use only.

Catalog No.S1006

217 publications

Saracatinib (AZD0530) Chemical Structure

CAS No. 379231-04-6

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Selleck's Saracatinib (AZD0530) has been cited by 217 publications

Science, 2019, 365(6454)

PubMed: 31320558 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(1):35-49

PubMed: 29249464 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):807-822

PubMed: 30423298 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2021, 208:111693

PubMed: 33396024 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107796

PubMed: 32579923 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 24;30(12):4235-4249e6

PubMed: 32209481 ( click the link to review the publication )

Cell Rep, 2020, 33(7):108398

PubMed: 33207193 ( click the link to review the publication )

Sci Signal, 2020, 13(650)eaba5754

PubMed: 32963013 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):148

PubMed: 32746865 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

J Neurosci, 2020, 40(34):6522-6535

PubMed: 32690613 ( click the link to review the publication )

Cell Death Dis, 2020, 12;11(2):118

PubMed: 32051399 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

PLoS Genet, 2020, 16(3):e1008694

PubMed: 32196488 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 43(2):311-320

PubMed: 31832986 ( click the link to review the publication )

J Immunol, 2020, 205(7):1953-1961

PubMed: 32848033 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.0186.2020

PubMed: 33004621 ( click the link to review the publication )

Front Oncol, 2020, 3;10:442

PubMed: 32346533 ( click the link to review the publication )

Cell Microbiol, 2020, e13240

PubMed: 32584493 ( click the link to review the publication )
Int J Mol Sci, 2020, 21(23)E9276

PubMed: 33291786 ( click the link to review the publication )

Sci Rep, 2020, 9;10(1):4355

PubMed: 32152351 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2020, 10.1152/ajplung.00444.2019

PubMed: 33325804 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.012957

PubMed: 32934005 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015489

PubMed: 33037073 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2020, 10.1152/ajpcell.00290.2020

PubMed: 32966125 ( click the link to review the publication )

Molecules, 2020, 8;25(9) pii: E2220

PubMed: 32397330 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12982

PubMed: 32737414 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:2139-2151

PubMed: 32210580 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):31

PubMed: 31931755 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0224952

PubMed: 32692785 ( click the link to review the publication )

Neoplasia, 2020, 22(3):129-141

PubMed: 31981897 ( click the link to review the publication )

J Invest Dermatol, 2020, S0022-202X(20)31981-3

PubMed: 32805217 ( click the link to review the publication )

Cells, 2020, 9(8):E1807

PubMed: 32751526 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):296

PubMed: 30655532 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4349

PubMed: 31554791 ( click the link to review the publication )

J Exp Med, 2019, 216(4):807-830

PubMed: 30819724 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(5):1639-1649

PubMed: 30504425 ( click the link to review the publication )

J Cell Biol, 2019, 218(9):3060-3076

PubMed: 31308216 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Cell Rep, 2019, 29(5):1311-1322.e5

PubMed: 31665642 ( click the link to review the publication )
J Hematol Oncol, 2019, 12(1):132

PubMed: 31805962 ( click the link to review the publication )

Mol Metab, 2019, 28:36-47

PubMed: 31327757 ( click the link to review the publication )

Br J Cancer, 2019, 10.1038/s41416-019-0608-1

PubMed: 31649319 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(6):1193-1203

PubMed: 31867165 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2135-2145

PubMed: 31484705 ( click the link to review the publication )

J Immunol, 2019, 203(11):2990-2999

PubMed: 31619538 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2019, 316(3):C377-C392

PubMed: 30566391 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Dev Comp Immunol, 2019, 96:1-8

PubMed: 30822451 ( click the link to review the publication )

Oncol Rep, 2019, 41(3):1911-1917

PubMed: 30628679 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3625-3632

PubMed: 31485668 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(4)e201900425

PubMed: 31331982 ( click the link to review the publication )

Commun Biol, 2019, 2:156

PubMed: 31098401 ( click the link to review the publication )

Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

Cancer Res, 2019, 79(19):5074-5087

PubMed: 31416844 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2068

PubMed: 29802342 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4259

PubMed: 30323235 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cancer Res, 2018, 78(4):985-1002.

PubMed: 29279356 ( click the link to review the publication )

Cancer Res, 2018, 78(22):6497-6508

PubMed: 30262461 ( click the link to review the publication )
J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(21):2817-2836

PubMed: 29511352 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )

Oncogene, 2018, 37(23):3166-3182

PubMed: 29545604 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):887

PubMed: 30166523 ( click the link to review the publication )

FASEB J, 2018, 32(6):3033-3046

PubMed: 29401603 ( click the link to review the publication )

Neurobiol Dis, 2018, 110:102-121

PubMed: 29197620 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Metallomics, 2018, 10(8):1141-1159

PubMed: 30066004 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Exp Cell Res, 2018, 364(2):208-216

PubMed: 29427623 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):922

PubMed: 30253737 ( click the link to review the publication )

Cancer Med, 2018, 7(2):408-419

PubMed: 29318780 ( click the link to review the publication )

Cancer Med, 2018, 7(3):820-830

PubMed: 29383859 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 502(1):110-115

PubMed: 29787755 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):447-454

PubMed: 29749519 ( click the link to review the publication )

Viruses, 2018, 10(6)

PubMed: 29795047 ( click the link to review the publication )

Tumour Biol, 2018, 40(8):1010428318794217

PubMed: 30124118 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10723-10733

PubMed: 29535838 ( click the link to review the publication )
Nat Cell Biol, 2017, 19(2):106-119

PubMed: 28114269 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

J Clin Invest, 2017, 127(4):1338-1352

PubMed: 28240606 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

J Natl Cancer Inst, 2017, 1;109(9):djx014

PubMed: 28376152 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

J Exp Med, 2017, 214(9):2715-2732

PubMed: 28838952 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):1643-1648

PubMed: 28130546 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3571-3590

PubMed: 28972102 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2990-3000

PubMed: 28416483 ( click the link to review the publication )

Cell Rep, 2017, 20(12):2775-2783

PubMed: 28930674 ( click the link to review the publication )

Cell Rep, 2017, 20(4):999-1015

PubMed: 28746882 ( click the link to review the publication )

Cell Rep, 2017, 21(2):533-545

PubMed: 29020637 ( click the link to review the publication )

Cell Rep, 2017, 18(3):804-815

PubMed: 28099856 ( click the link to review the publication )

Sci Signal, 2017, 10(460)

PubMed: 28049762 ( click the link to review the publication )

J Med Chem, 2017, 60(18):7863-7875

PubMed: 28792760 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

J Virol, 2017, 91(21)

PubMed: 28814523 ( click the link to review the publication )

PLoS Comput Biol, 2017, 13(3):e1005432

PubMed: 28306714 ( click the link to review the publication )

J Cancer, 2017, 8(11):1943-1951

PubMed: 28819393 ( click the link to review the publication )
Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Leuk Res, 2017, 61:44-52

PubMed: 28888102 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):494-506

PubMed: 28346091 ( click the link to review the publication )

Cancer Genet, 2017, 216-217:128-141

PubMed: 29025587 ( click the link to review the publication )

Biotechnol J, 2017, 12(10)

PubMed: 28786556 ( click the link to review the publication )

J Exp Med, 2017, 214(9):2715-2732

PubMed: 28838952 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103014-103031

PubMed: 29262541 ( click the link to review the publication )

Oncotarget, 2017, 8(48):83872-83889

PubMed: 29137389 ( click the link to review the publication )

Oncotarget, 2017, 9(5):5545-5561

PubMed: 29464017 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Oncotarget, 2017, 8(61-:103014-103031

PubMed: 29262541 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Sci Transl Med, 2016, 8(354):354ra114

PubMed: 27582059 ( click the link to review the publication )

Theranostics, 2016, 6(4):594-609

PubMed: 26941850 ( click the link to review the publication )

Cancer Res, 2016,

PubMed: 27216177 ( click the link to review the publication )

Sci Signal, 2016, 9(448):ra97

PubMed: 27703030 ( click the link to review the publication )

Brain Behav Immun, 2016, 55:236-248

PubMed: 26721416 ( click the link to review the publication )

Cell Death Dis, 2016, 7(12):e2572

PubMed: 28032865 ( click the link to review the publication )

PLoS Genet, 2016, 12(3):e1005931

PubMed: 26978032 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(9):2198-208

PubMed: 27256378 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(2):266-74

PubMed: 26604135 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(2):509-21

PubMed: 27186420 ( click the link to review the publication )
J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(10):1555-68

PubMed: 26976639 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

Toxicology, 2016, 370:94-105

PubMed: 27693619 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 479(3):563-570

PubMed: 27666484 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27285768 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Sci Signal, 2015, 8(400):ra106

PubMed: 26508788 ( click the link to review the publication )

Stem Cells, 2015, 10.1002/stem.1990

PubMed: 25788415 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2238-48

PubMed: 26208525 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):377-88

PubMed: 25306394 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(15):4296-305

PubMed: 25948553 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(12):2687-96

PubMed: 26390252 ( click the link to review the publication )

FEBS J, 2015, 10.1111/febs.13314

PubMed: 25940608 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Pancreas, 2015, 44(1):152-7

PubMed: 25222135 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0142219

PubMed: 26556238 ( click the link to review the publication )

Mol Cell Biochem, 2015, 407(1-2):197-207

PubMed: 26045172 ( click the link to review the publication )

J Biomol Screen, 2015, 20(10):1286-93

PubMed: 26384394 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Nature, 2015, 519(7541):57-62

PubMed: 25731159 ( click the link to review the publication )
Oncotarget, 2015, 6(26):22098-113

PubMed: 26061747 ( click the link to review the publication )

Oncotarget, 2015, 6(30):29991-30005

PubMed: 26358373 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9476-87

PubMed: 25823815 ( click the link to review the publication )

Neurotherapeutics, 2015, 12(1):132-42

PubMed: 25549849 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25897-916

PubMed: 26317790 ( click the link to review the publication )

Oncotarget, 2015, 6(26):22098-113

PubMed: 26061747 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(5):401-14

PubMed: 24705551 ( click the link to review the publication )

J Clin Invest, 2014, 124(12):5490-502

PubMed: 25401474 ( click the link to review the publication )

J Clin Invest, 2014, 124(7):3003-15

PubMed: 24911146 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4762-71

PubMed: 25023728 ( click the link to review the publication )

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(3):R45

PubMed: 24887236 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-38

PubMed: 24482380 ( click the link to review the publication )

Cancer Sci, 2014, 105(5):528-36

PubMed: 24612061 ( click the link to review the publication )

J Chem Inf Model, 2014, 54(3):881-93

PubMed: 24490903 ( click the link to review the publication )

Ultrasound Med Biol, 2014, 40(6):1177-86

PubMed: 24612644 ( click the link to review the publication )

Placenta, 2014, 35(10):824-30

PubMed: 25108485 ( click the link to review the publication )

Oncotarget, 2014, 6(3)

PubMed: 25596741 ( click the link to review the publication )

University of Manche, 2014, aus Landshut

PubMed: ( click the link to review the publication )

J Neurooncol, 2014, 120(1):33-41

PubMed: 25048528 ( click the link to review the publication )

Oncotarget, 2014, 5(19):8853-68

PubMed: 25326682 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )
Pac Symp Biocomput, 2014, 2014:125-35

PubMed: 24297540 ( click the link to review the publication )

Dissertation zur Erlangung des Doktorgrades, 2014,

PubMed: ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Cell Biol, 2013, 15(4):395-405

PubMed: 23455479 ( click the link to review the publication )

Blood, 2013, 122(7):1203-13

PubMed: 23836556 ( click the link to review the publication )

J Clin Invest, 2013, 123(5):2037-48

PubMed: 23543053 ( click the link to review the publication )

Int J Cancer, 2013, 132(1):224-35

PubMed: 22623106 ( click the link to review the publication )

Breast Cancer Res, 2013,

PubMed: 24044505 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e915

PubMed: 24201814 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

Biochimica et Biophysica Acta, 2013, 1829(10):1147-59

PubMed: 23948603 ( click the link to review the publication )

Mol Carcinog, 2013, 10.1002/mc.22092

PubMed: 24127286 ( click the link to review the publication )

PLoS One, 2013, 8(4):e60889

PubMed: 23593342 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(6):379-88

PubMed: 22313687 ( click the link to review the publication )

Cancer Res, 2011, 71(24):7547-57

PubMed: 21994334 ( click the link to review the publication )

Mol Cancer Res, 2011, 9(3):249-58

PubMed: 21296861 ( click the link to review the publication )

Mol Endocrinol, 2011, 25(12):2041-53

PubMed: 22053001 ( click the link to review the publication )

Cancer Biol Ther, 2011, 12(3):215-28

PubMed: 21642769 ( click the link to review the publication )

Transl Oncol, 2011, 4(2):92-100

PubMed: 21461172 ( click the link to review the publication )

Methods Mol Biol, 2011, 685:91-109

PubMed: 20981520 ( click the link to review the publication )
Mol Endocrinol, 2010, 24(6):1151-64

PubMed: 20371703 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description

Features

The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Targets

c-Src ^[2] (Cell-free assay)	LCK ^[2] (Cell-free assay)	c-YES ^[2] (Cell-free assay)	EGFR (L861Q) ^[2] (Cell-free assay)	Lyn ^[2] (Cell-free assay)	View More
2.7 nM	<4 nM	4 nM	4 nM	5 nM	View More

In vitro

Saracatinib also potently inhibits other Src tyrosine kinase family members including c-Yes, Fyn, Lyn, Blk, Fgr, and Lck with IC50 from 4-10 nM. Saracatinib sensitively inhibits Src Y530F NIH 3T3 with IC50 of 80 nM. Saracatinib signiﬁcantly impairs the invasion of HT1080 cells through a 3-dimensional collagen matrix and completely inhibits EGF-induced cell scattering in NBT-II bladder cancer cells. ^[1] Saracatinib potent inhibits Src activation in DU145 and PC3 cells, which through inhibition of Y419 phosphorylation. Saracatinib inhibits the growth of prostate cancer including PC3, DU145, CWR22Rv1 and LNCaP, while Saracatinib shows low activity in LAPC-4, PZ-HPV7 and RWPE-1 cells. Saracatinib induces cell cycle arrest at G1/S but not caspase 3 cleavages. Saracatinib also significantly inhibits DU145 and PC3 migration in the Boyden chamber. ^[2] Saracatinib gives a potent and sustained blockage of AKT and enhances the sensitivity to irradiation in A549 and Calu-6 cells. ^[3] Saracatinib inhibits osteoclast in activity, resorption and formation. Saracatinib also reversibly prevents osteoclast precursor migration. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
CTV-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFnyTnpKSzVyPUCuNFYyPDNizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
LAMA-84	MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NE\3cFdKSzVyPUCuNVU6QSEQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
MEG-01	MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MX\JR\|UxRTBwMkO2PFgh\|ryP	Ml3VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
EM-2	NFjFfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3jKU2lEPTB;MD6yOlUh\|ryP	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
TE-15	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFnH[2VKSzVyPUCuNlc1OTJizszN	MkLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
NCI-H1648	NV2wPGl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVXJR\|UxRTBwMkixNVYh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
TE-12	NETwd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHjuPHBKSzVyPUCuN\|I3QCEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
LB996-RCC	M2DTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYjJR\|UxRTBwNESxPVYh\|ryP	NXnGd2xvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
K-562	MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVrxNVJQUUN3ME2wMlQ1QTZ5IN88US=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
D-336MG	MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mom0TWM2OD1yLkWwN\|A1KM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NOS-1	NF;GSY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFSx[2JKSzVyPUCuOlA2OjlizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
EW-24	M3e1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MofJTWM2OD1yLk[yOlk{KM7:TR?=	NIDFWZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
BV-173	NWjTWXBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHLG[FZKSzVyPUCuOlUzPDlizszN	NUf5TmpYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
NCCIT	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVXue3ZIUUN3ME2wMlc{OjF6IN88US=>	M3XYflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NCI-H1436	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlHDTWM2OD1yLke5NFQ6KM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
BB30-HNC	Moj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mmr3TWM2OD1yLki2NlA{KM7:TR?=	NYj1N2Z1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
TE-8	M4TWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV3JR\|UxRTBwOEeyO\|Uh\|ryP	NXSwNFl7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
A704	NIfhTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NE[1bZlKSzVyPUCuPFkzOSEQvF2=	Mo\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
TK10	NEPVS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWfObGw3UUN3ME2wMlkxPjZ7IN88US=>	NGTpNpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
KS-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXjFO\|NzUUN3ME2xMlE6Pzd7IN88US=>	NV2zRYNuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
C2BBe1	NFq0b3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHLpT4ZKSzVyPUGuNlA2ODdizszN	M{PIeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
RXF393	MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnfGTWM2OD1zLkK0N\|Yh\|ryP	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
KGN	NGnDSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIG0fmRKSzVyPUGuNlc3QDdizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NB69	M1[3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHHW[nBKSzVyPUGuN\|c1QTdizszN	NH\ZXFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
TE-11	NFfP[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUnJR\|UxRTFwNEO0NVgh\|ryP	NXnmfZpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
TE-1	Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUXtSHZpUUN3ME2xMlQ1OTB3IN88US=>	M1SwTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
ST486	NIe4Wm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{XnTGlEPTB;MT60OVg2OiEQvF2=	NF\1R2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
HOP-62	M4q4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mn:1TWM2OD1zLkWwNlQ3KM7:TR?=	NFXDRmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
EW-16	M3HDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NH3GfoxKSzVyPUGuOVUxQDNizszN	NYeyT45KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
LB1047-RCC	M1;6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWjJR\|UxRTFwNUW0OVMh\|ryP	NWf4U2xHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
TE-10	NYDrOXpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHnP[5ZKSzVyPUGuOlYzPTJizszN	M3ztU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
RL95-2	NIfnWHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2TINmlEPTB;MT62OlkxOiEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
DOHH-2	NFTtV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{PSdGlEPTB;MT63NVc5OiEQvF2=	NWrvb3B5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
MFH-ino	NYfYe25WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUHlPXlXUUN3ME2xMlc4QDdizszN	NUfEcVVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
GB-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFfFbYhKSzVyPUGuO\|k5OzNizszN	NFTCfXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
SK-N-DZ	NF\xbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHHYOpZKSzVyPUGuPFQ3QDhizszN	NGfVXYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
OS-RC-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGj6TXBKSzVyPUGuPFg2PzRizszN	MoX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SW982	M3\Rc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mn\zTWM2OD1zLkmyNFk{KM7:TR?=	NEDRZ3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
KALS-1	NH6wZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4LiUmlEPTB;MT65PFczOiEQvF2=	NILOV2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
TGBC24TKB	MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlHLTWM2OD1{LkC1PVU5KM7:TR?=	NWfGOnVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
GI-1	M3LWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUPPdmY{UUN3ME2yMlE3ODh2IN88US=>	MoXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SW962	NV;TOohoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mmi3TWM2OD1{LkG3NVc5KM7:TR?=	MkniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SW872	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmjaTWM2OD1{LkG4OVA4KM7:TR?=	M3;KeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NCI-H747	NIXJWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NX3JeZFYUUN3ME2yMlI2PzF2IN88US=>	MoKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
MZ1-PC	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXnJR\|UxRTJwMkmzOVYh\|ryP	M4Llb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
MSTO-211H	NU\vOI9VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVLrfGxyUUN3ME2yMlM2PzJ\|IN88US=>	MmHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
BL-70	NGLHfHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIjNWolKSzVyPUKuOFc1OjJizszN	M4KzR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SW954	NGGzeYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmjjTWM2OD1{LkW3OFA5KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SNB75	Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NILabmxKSzVyPUKuOlg2QTRizszN	MoLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
IST-SL2	NUfqTXlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1vMc2lEPTB;Mj63NlM4QSEQvF2=	MoX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
GCIY	NVLIUpFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYLJR\|UxRTJwOEewNFUh\|ryP	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
KU812	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYqz[ZhUUUN3ME2zMlA2Ojl7IN88US=>	MkLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
LXF-289	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYLJR\|UxRTNwMUKxNFkh\|ryP	NF32UFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
ETK-1	MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmrPTWM2OD1\|LkKwO\|Y4KM7:TR?=	NHvIVJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
SF126	M3nQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYXJR\|UxRTNwM{GxO\|Qh\|ryP	MnXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
LC-2-ad	NFnnem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXztRZNnUUN3ME2zMlU2PyEQvF2=	MnrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
KNS-42	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NX7kS5ZpUUN3ME2zMlY2KM7:TR?=	NFjQWVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
OVCAR-4	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NInObYlKSzVyPUOuO\|M1OzNizszN	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
PF-382	NEHiU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NY[4SG9pUUN3ME2zMlg{Pjl6IN88US=>	NUTsOGtjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
SH-4	NFy0NIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml7aTWM2OD12LkK1NlU6KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
KM12	M4eybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4LuNGlEPTB;ND6zNlQyPiEQvF2=	NF\He3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
NB5	Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWTlPG0zUUN3ME20MlQyQDZ2IN88US=>	NWPid4JwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KURAMOCHI	NYLKUGVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NETwTVNKSzVyPUSuOlUzPTZizszN	NWLBc25XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
Becker	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NW\5NndCUUN3ME20MlY3PDF4IN88US=>	M4X6XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
MV-4-11	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnnhTWM2OD12LkixN\|Q1KM7:TR?=	NHfid\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
KINGS-1	NVftW3JuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1;YXmlEPTB;ND64NlM4OyEQvF2=	NGO1RVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
LS-123	M{fobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHLqcIlKSzVyPUWuOFk3QDRizszN	NHHodmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
SF268	NUewOZR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnzyTWM2OD13Lk[xNlYzKM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
A388	NUT0fZVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2PLSWlEPTB;NT62N\|Y3PyEQvF2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NMC-G1	M4jIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHzQbnZKSzVyPU[uNFE5OTFizszN	M{HCTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
CGTH-W-1	M2PYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGXRdIdKSzVyPU[uNFIxPzVizszN	MlH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
ES4	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3PHUmlEPTB;Nj61N\|A4PCEQvF2=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SR	MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1jneGlEPTB;Nj61PFgxPyEQvF2=	NUPLc\|ZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
BB49-HNC	MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVvJR\|UxRTZwN{OyNFYh\|ryP	NXTkcoE3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KLE	M322W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3PhPGlEPTB;Nj63PFM4PyEQvF2=	Ml;xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
HUTU-80	M4nF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmHaTWM2OD14Lkm4OFY3KM7:TR?=	NUj1[IdNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
SNU-C2B	NI[2NpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUS5ZopFUUN3ME23MlgzPzN5IN88US=>	M3\LVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
BB65-RCC	MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NU\VZZJzUUN3ME23Mlk1QTB2IN88US=>	NXnYTGxpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
QIMR-WIL	M{jEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXizO41pUUN3ME24MlQzQDB6IN88US=>	NVTEN41YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
GDM-1	MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWXJR\|UxRThwOUeyPVIh\|ryP	M4PoNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
LC4-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Ml;LTWM2OD17LkCwPVEyKM7:TR?=	M4mxUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
MLMA	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIPQSm9KSzVyPUmuNVUxODZizszN	MknUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
EoL-1-cell	MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnXYTWM2OD17LkOwNVkzKM7:TR?=	NIDhO409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
BOKU	NYTGdll1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnLCTWM2OD17Lkm2OFY3KM7:TR?=	NVr5eIdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
EVSA-T	MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYTvbo5SUUN3ME2xNE43PTZ6IN88US=>	NWPLNHlFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
D-283MED	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1O1[mlEPTB;MUCuPVE4PiEQvF2=	M4T4XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NB1	NYrQcY95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYjJR\|UxRTFzLkCyOFIh\|ryP	M{S4dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
RPMI-8402	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYnp[WdoUUN3ME2xNU4yPzhizszN	NWjkWY1wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
NCI-H1355	NGWzXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWXJR\|UxRTFzLkG4NFYh\|ryP	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NB7	NVzUZWJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXjJR\|UxRTFzLkOyPVch\|ryP	NFK5S\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
RPMI-6666	M2myWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Ml3yTWM2OD1zMj65OVY4KM7:TR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
697	NFXodVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3nLN2lEPTB;MUOuNlcxOSEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
CTB-1	NIPadFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXHle4Q4UUN3ME2xN{42QTR6IN88US=>	NI\UOFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
VA-ES-BJ	NV;rfHBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1vkVWlEPTB;MUOuPVI{PCEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
BE-13	NHXkNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIHXN5hKSzVyPUG0MlM6OTVizszN	NVXId4YxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
SKM-1	MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{DO[GlEPTB;MUSuOFQ6QSEQvF2=	NGDW[G49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
TE-6	NXPZV3pTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGe4OFVKSzVyPUG0Mlc2QTFizszN	NI\3e5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
LB771-HNC	M3fmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXfWbppQUUN3ME2xOE44QDl6IN88US=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
ECC4	M{O4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUnJR\|UxRTF5LkCyO\|ch\|ryP	M{fJVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
ES3	MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFrOPXZKSzVyPUG3MlQ3PTVizszN	M2LVc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
LB647-SCLC	NIDYfHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUHJR\|UxRTF5LkS5OFkh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NB10	MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXTJR\|UxRTF6LkWyOVYh\|ryP	MlnLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
L-540	M1;TWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYDJR\|UxRTF6LkixNFkh\|ryP	Mn[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
NCI-H2126	Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIr5PJNKSzVyPUG5MlUyKM7:TR?=	MmLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
HH	M3Wye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFjOd4hKSzVyPUKwMlAxQTlizszN	NIGzWnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
MPP-89	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUPrPYhOUUN3ME2yN{4zOjh7IN88US=>	M2DQcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
IST-MEL1	NH64Sm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUfBZWNJUUN3ME2yN{45PjV6IN88US=>	NWfyWYhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KP-N-YS	NFPiTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUC1OZRKUUN3ME2yN{46OjV3IN88US=>	NWnNdFhMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
EC-GI-10	Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYXJR\|UxRTJ2LkW5PFkh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
EKVX	NGjhZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkfITWM2OD1{Nj6wNlA{KM7:TR?=	MmG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
TGBC1TKB	MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mki0TWM2OD1{Nj60N\|Qh\|ryP	NYDVVlZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
Daudi	M2nNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHfROZZKSzVyPUK3MlA4PzNizszN	NGnGcI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
ALL-PO	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1TlbWlEPTB;MkeuNFgyKM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NB6	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWjJR\|UxRTJ5LkS4PEDPxE1?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
ES6	NUfuSVVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{K1TmlEPTB;MkeuPVEzOyEQvF2=	NUCzOZVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
COLO-320-HSR	M3THcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVfMeWxVUUN3ME2yPE4xOzd\|IN88US=>	MkHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
K5	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1v6[WlEPTB;MkiuNVI5PyEQvF2=	NGPGWFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
ES1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIq4co5KSzVyPUK4Mlc4PzNizszN	MmqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
LC-1F	M4r4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2L4fGlEPTB;MkmuO\|M1PiEQvF2=	M2C5N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SCLC-21H	NH6wWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1;wR2lEPTB;M{CuO\|MyPyEQvF2=	NHT1cHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
SK-PN-DW	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NV\n[5lPUUN3ME2zNk42PTl6IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
D-247MG	MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXLUZmdQUUN3ME2zNk46Pzd\|IN88US=>	NHTFdFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
TE-5	NHH4OlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4SzbmlEPTB;M{OuNFM3OiEQvF2=	MmrqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
MONO-MAC-6	Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MX\JR\|UxRTN\|LkWwOFgh\|ryP	NF\ncpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
LB2518-MEL	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MorjTWM2OD1\|Mz63OlY3KM7:TR?=	NIDsOnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
LOXIMVI	M3jjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2X0cGlEPTB;M{OuO\|kzQCEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NCI-H209	MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NELVRnNKSzVyPUO1MlE1PCEQvF2=	NVvUbYRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
A253	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NW\JWZJSUUN3ME2zOU44PDJ7IN88US=>	M3r1SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
HCC1599	M2HSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4O2RWlEPTB;M{[uO\|A2OyEQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
EB-3	M4nKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MY\JR\|UxRTN4Lkm1NVgh\|ryP	M1v4clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
GOTO	M1rCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVj4[JhmUUN3ME2zO{4{OjJ2IN88US=>	NHXGcpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
SW684	NU[2Zot1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MonhTWM2OD12MT64OFk2KM7:TR?=	NFjzR3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
DEL	NXPpNXZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVjJR\|UxRTR{LkC1NlIh\|ryP	NFz1N5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
HT-144	NHfleWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGW5SoxKSzVyPUSyMlE3PzZizszN	NF7sRYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
TE-9	M4PDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEn1U5hKSzVyPUSzMlQ2QTZizszN	NVj2So4xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KARPAS-45	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4jEU2lEPTB;NESuN\|kzPSEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
HAL-01	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFjRcZdKSzVyPUS0MlUxOzRizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
RCC10RGB	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXfuWVFCUUN3ME20OE44Ozl{IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
CP67-MEL	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3PIc2lEPTB;NEWuOlI1OSEQvF2=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NB17	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXPJR\|UxRTR3Lk[2OFMh\|ryP	M{L1PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SK-UT-1	NE\j[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEjFS5JKSzVyPUS1Mlk1PjRizszN	NV\JNJhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
JiyoyeP-2003	NV3iNYoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1PJ[GlEPTB;NE[uNFEyQSEQvF2=	MoKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
HCE-4	NUPX[W8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVrJR\|UxRTR4LkW5Olgh\|ryP	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NCI-H720	M4HncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2\BUGlEPTB;NE[uO\|Y5OiEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
KARPAS-422	NHXxOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXK3dnhQUUN3ME20O{4xQDl3IN88US=>	M3fqV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	M4rSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Ml\XTWM2OD12Nz6xOlIzKM7:TR?=	NXv5N\|l7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
HCE-T	NH21PJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkDQTWM2OD12Nz62PFI5KM7:TR?=	NHHN[pI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
PSN1	NW\RbXVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3LlcmlEPTB;NEeuO\|gyOyEQvF2=	M1naVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NIH3T3	NUL5XZlDTnWwY4Tpc44h[XO\|YYm=			Mm\GTY5pcWKrdHnvckBw\iCqdX3hckBkNVO{YzDpckBPUUh\|VEOgZ4VtdHNuIFnDOVAhRSByLkCwNlch\|ryPLh?=	NFz5OlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{C2OFA3Pid-MUewOlQxPjZ:L3G+
HEK293	NVrPR3NDTnWwY4Tpc44h[XO\|YYm=		NV;KXYNuOSCqch?=	MYfJcohq[mm2aX;uJI9nKGi3bXHuJIZ2dGxibHXu[5RpKFCNTWnUNUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJJV{cW6pIFXGV{ApOjR5IITvJFI2QSC{ZYPp[JVmeyliYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCrbX31co9ie2G7LDDLbUA:KDBwMEO5PEDPxE1w	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl2MUG5N{c,Ojl7NEGxPVM9N2F-
HEK293	MY\GeY5kfGmxbjDhd5NigQ>?		M1Tu[\|EhcHJ?	NVTVfmN6UW6qaXLpeIlwdiCxZjDoeY1idiCodXzsJIxmdme2aDDQT21[XDFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC3c3nu[{BGTlNiKEK0O{B1dyB{NUmgdoV{cWS3ZYOpJIF{KHO3YoP0doF1\SCjZoTldkAyKGi{IHL5JIZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gbY1ufW6xYYPhfUwhUUN3MDC9JFAvPDF6IN88UU4>	M2TxNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUSxNVk{Lz5{OUm0NVE6OzxxYU6=
Rh30	MnvhRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MkDrOFghcHK\|	NXHV[3FZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSbFMxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W62IHHzd4F6NCCLQ{WwJF0hOTBwMTFOwG0v	NHnkbIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e4O\|A6QSd-MkO3PFcxQTl:L3G+
Huh7	M1jSc2FvfGm4aYLhcEBie3OjeR?=	Mm\2Nk42KHWP	Mni3OUBl[Xm\|	MkeyTY5pcWKrdHnvckBw\iC4aYLhcEB{eHKnYXSgbY4hTGWwZ4XlJJZqenW\|LXnu[oVkfGWmIHj1cYFvKEi3aEegZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKG:oII\pdoFtKGWwdnXsc5BmKHC{b4TlbY4hf2m2aHnuJJBmemmwdXPs[YFzKHKnZ3nvckBifCB{LkWgeW0h[W[2ZYKgOUBl[Xm\|IHL5JIludXWwb3\seY9z\XOlZX7j[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;s	M3riR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{[wOlc3Lz5zN{O2NFY4PjxxYU6=
Huh7	NXnnVpJ5SW62aY\pdoFtKGG\|c3H5	NIrvVXozNjVidV2=	NWTBVYY{PiCmYYnz	NGDGO3hKdmirYnn0bY9vKG:oII\pdoFtKHOycnXh[EBqdiCGZX7neYUhfmm{dYOtbY5n\WO2ZXSgbJVu[W5iSIXoO{Bk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[geolz[WxiZX72[YxweGVicILveIVqdiC5aYTobY4heGW{aX71Z4xm[XJicnXnbY9vKGG2IEKuOUB2VSCjZoTldkA3KGSjeYOgZpkhcW2vdX7v[ox2d3Knc3PlcoNmKGG\|c3H5JJJmdGG2aY\lJJRwKGOxboTyc4w>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4ME[3Okc,OTd\|NkC2O\|Y9N2F-
Vero	MmTpRY51cX[rcnHsJIF{e2G7	M13TXVIvPSC3TR?=	NYLiNXdZPCCmYYnz	M{S5RmlvcGmkaYTpc44hd2ZidnnyZYwhe3C{ZXHkJIlvKESnbnf1[UB3cXK3cz3pcoZm[3SnZDDh[pJq[2GwIHfy[YVvKG2xbnvlfUBX\XKxIHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXNJIFnfGW{IESg[IF6eyCkeTDpcY12dm:obIXvdoV{[2WwY3WgZZN{[XlicnXsZZRqfmVidH:gZ49vfHKxbB?=	MlHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|NkC2O\|YoRjF5M{[wOlc3RC:jPh?=
Vero	NUOwPI5RSW62aY\pdoFtKGG\|c3H5	M4DzZlIvPSC3TR?=	NH:1boQ3KGSjeYO=	Mn;3TY5pcWKrdHnvckBw\iC4aYLhcEB{eHKnYXSgbY4hTGWwZ4XlJJZqenW\|LXnu[oVkfGWmIHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JHZmem9iY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2gZYZ1\XJiNjDkZZl{KGK7IHntcZVvd2[udX;y[ZNk\W6lZTDhd5NigSC{ZXzheIl3\SC2bzDjc451em:u	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4ME[3Okc,OTd\|NkC2O\|Y9N2F-
C6/36	MlvDRY51cX[rcnHsJIF{e2G7	NYL5eml2Oi53IIXN	M3iwO\|Qh\GG7cx?=	NVzObI1SUW6qaXLpeIlwdiCxZjD2bZJidCC\|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVOKGGodHXyJFQh\GG7czDifUBqdW23bn;mcJVwemW\|Y3XuZ4Uh[XO\|YYmgdoVt[XSrdnWgeI8h[2:wdILvcC=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4ME[3Okc,OTd\|NkC2O\|Y9N2F-
C6/36	M1jJXGFvfGm4aYLhcEBie3OjeR?=	M1nrSFIvPSC3TR?=	NFrrR5c2KGSjeYO=	M4jKdWlvcGmkaYTpc44hd2ZidnnyZYwhe3C{ZXHkJIlvKESnbnf1[UB3cXK3cz3pcoZm[3SnZDDhd4lidiC2aXfldkBud3OzdXn0c{BEPi9\|NjDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44hd2ZidnnyZYwh\W64ZXzvdIUheHKxdHXpckB4cXSqaX6gdIVzcW63Y3zlZZIhemWpaX;uJIF1KDJwNTD1UUBi\nSncjC1JIRigXNiYomgbY1ufW6xZnz1c5Jme2OnbnPlJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3y=	MmO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|NkC2O\|YoRjF5M{[wOlc3RC:jPh?=
Vero	MYLBcpRqfmm{YXygZZN{[Xl?		M3i5bFMh\GG7cx?=	M1G5TmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGRmdme3ZTD2bZJ2eyCrbn\lZ5Rm\CCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBX\XKxIHPlcIx{KGGmbXnubZN1\XKnZDDh[pRmeiC4aYLhcEBkcGGubHXu[4Uh[W[2ZYKgN{Bl[Xm\|IHL5JJZqemGuIIDsZZF2\SCjc4PhfS=>	NH;ZZmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O2NFY4Pid-MUezOlA3PzZ:L3G+
Vero	MYTBcpRqfmm{YXygZZN{[Xl?	NIDIV\|MzNjVidV2=	NWjwOVByPSCmYYnz	MWXJcohq[mm2aX;uJI9nKH[rcnHsJJNxemWjZDDpckBF\W6pdXWgeolzfXNvaX7m[YN1\WRiYX\ybYNidiCpcnXlckBud26tZYmgWoVzdyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TTDh[pRmeiB3IHThfZMh[nliaX3teY5w\my3b4Lld4NmdmOnIHHzd4F6KHKnbHH0bZZmKHSxIHPvcpRzd2x?	NWHoc4hqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlA3PzZpPkG3N\|YxPjd4PD;hQi=>
Huh7	Moj4RY51cX[rcnHsJIF{e2G7	MWCyMlUhfU1?	NEizRXg1KGSjeYO=	MnHOTY5pcWKrdHnvckBw\iC4aYLhcEB{eHKnYXSgbY4hTGWwZ4XlJJZqenW\|LXnu[oVkfGWmIHj1cYFvKEi3aEegZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKG:oII\pdoFtKGWwdnXsc5BmKHC{b4TlbY4hf2m2aHnuJJBmemmwdXPs[YFzKHKnZ3nvckBifCB{LkWgeW0h[W[2ZYKgOEBl[Xm\|IHL5JIludXWwb3\seY9z\XOlZX7j[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;s	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4ME[3Okc,OTd\|NkC2O\|Y9N2F-
C6/36	M3rwUWFvfGm4aYLhcEBie3OjeR?=	MnXWNk42KHWP	MoD0OkBl[Xm\|	NE\ZflBKdmirYnn0bY9vKG:oII\pdoFtKHOycnXh[EBqdiCGZX7neYUhfmm{dYOtbY5n\WO2ZXSgZZNq[W5idHnn[ZIhdW:\|cYXpeI8hSzZxM{[gZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKG:oII\pdoFtKGWwdnXsc5BmKHC{b4TlbY4hf2m2aHnuJJBmemmwdXPs[YFzKHKnZ3nvckBifCB{LkWgeW0h[W[2ZYKgOkBl[Xm\|IHL5JIludXWwb3\seY9z\XOlZX7j[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;s	NUjmUGFHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlA3PzZpPkG3N\|YxPjd4PD;hQi=>
HEK293	M{n5OmZ2dmO2aX;uJIF{e2G7	M17JWFAvOSC2bzCxJJVO	MmLLNVYhcHK\|	MW\Jcohq[mm2aX;uJI9nKGOxbHzh[4VvKElvaX7keYNm\CCGRGKyJEh2dmuwb4fuJI9zcWerbjmgdIhwe3Cqb4L5cIF1cW:wIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYSgNE4yKHSxIEGgeW0h[W[2ZYKgNVYhcHK\|IHL5JHdme3Sncn6gZoxwfHSrbne=	M3vNWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUmxN\|Y6Lz5{NkG5NVM3QTxxYU6=
A673	M2HvS5FJXFNiYYPzZZk>			MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	M3PLVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	NV7oV3lReUiWUzDhd5NigQ>?			NHn0eGxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	M121d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	NH:2RoVyUFSVIHHzd4F6			MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	MVfxTHRUKGG\|c3H5			M{PmdJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	M2jnVZFJXFNiYYPzZZk>			MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	Mmm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	NVzSZoVneUiWUzDhd5NigQ>?			NHPWVFFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	MljmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MojwdWhVWyCjc4PhfS=>			M1PUNJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	M2PZfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NIXTWI9yUFSVIHHzd4F6			M2e5SJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	NYfYdXg6eUiWUzDhd5NigQ>?			M2PnSZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	NH7Y[VU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
HEK293	NVXkbFltTnWwY4Tpc44h[XO\|YYm=	NXXCOmJVOC5zIITvJFEhfU1?	M3HJSlE3KGi{cx?=	MnOxTY5pcWKrdHnvckBw\iClb3zsZYdmdiCLLXnu[JVk\WRiRFTSNkBKPjN6RjDteZRidnRiKIXub45wf25ib4Lp[4lvMSCyaH;zdIhwenmuYYTpc44h\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsd{BifCByLkGgeI8hOSC3TTDh[pRmeiBzNjDodpMh[nliV3XzeIVzdiCkbH;0eIlv\w>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF7MUO2PUc,OjZzOUGzOlk9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pY576-FAK / pY861-FAK / FAK; PubMed: 20551056 Cancer Res (A) HCT116 (left) and WiDr (right) cells were exposed to the indicated concentrations of saracatinib for 24 hours and the effect on total FAK or FAK phosphorylation on tyrosine 576 or 861 was assessed by western blotting. Result is representative of three independent experiments. pY418 Src / Src / pY410 CAS / CAS / Py421 Cortactin / Cortactin; PubMed: 20505783 J Cancer Sci Ther Saracatinib inhibits Src activity and downstream Src substrate phosphorylation in HNSCC cell lines. HN31, UMSCC1 and 1483 cells were treated with DMSO vehicle or saracatinib (0.01–1 μM) for 24 h. Cells were lysed and total protein amounts were analyzed by Western blotting with total or phosphorylation site-specific antibodies for Src and the indicated substrates. Blots shown are representative of at least four independent experiments, with band intensities for each substrate quantified relative to the untreated (0 μM) condition for each cell line. p-Akt / p-mTOR / Akt / mTOR / p-S6 / S6 / p-AMPKα / AMPKα; PubMed: 20811583 Genes Cancer PC3 cells were treated with 10 μM PP2 (left panel)/1 μM saracatinib (right panel) for 0.5, 1, 2, 4, 8, and 24 h. Cell lysates were analyzed by immunoblotting with antibodies as indicated. Controls were treated with vehicle alone. β-actin was detected as loading control.	20551056 20505783 20811583
Growth inhibition assay	Cell number; PubMed: 24349321 PLoS One LNCaP 104-S, 104-R1, 104-R2, PC-3, and DU-145 cells were treated with increasing concentrations of Saracatinib for 72 hrs. Relative cell number of LNCaP cells was determined by Hoechst dye 33258-based 96-well proliferation assay. Cell numbers were normalized to control (dimethylsulfoxide) of each cell line. Triple asterisks (***) represent statistically significant difference p <0.001 between the treated group and the control group.	24349321

In vivo

Saracatinib shows great tumor growth inhibition in Src3T3 allografts and a moderate growth delay in Calu-6, MDA-MB-231, AsPc-1 and BT474C xenografts. ^[1] Saracatinib shows great antitumor activity in orthotopic DU145 xenograft mice at a dose of 25mg/kg (orally administered, daily). ^[2]

Protocol

Kinase Assay: ^[1]	- Collapse Kinase Assay: IC50 of tyrosine kinase activity is measured by an enzyme-linked immunosorbent assay (ELISA) with recombinant catalytic domains of a panel of receptor and non-receptor tyrosine kinases (in some cases only part of the catalytic domain is used). Saracatinib dose ranges from 0.001-10 mM. Speciﬁcity assays against a panel of serine/threonine kinases are performed using a ﬁlter capture assay with ³²P. Brieﬂy, multidrop 384 plates containing 0.5 μL Saracatinib or controls (DMSO) alone or pH 3.0 buffer controls) are incubated with 15 μL of enzyme plus peptide/protein substrate for 5 min before the reaction is initiated by the addition of 10 μL of 20 mM Mg-ATP. For all enzymes the ﬁnal concentration is approximated to the Michaelis constant (K_m). Assays are carried out for 30min at room temperature before termination by the addition of 5 μL orthophosphoric acid. After mixing, the well contents are harvested onto a P81 Uniﬁlter plate, using orthophosphoric acid as the wash buffer. Then IC50 is calculated.
Cell Research: ^[1]	- Collapse Cell lines: PC3, DU145, CWR22Rv1, LNCaP, LAPC-4, PZ-HPV7 and RWPE-1 cells Concentrations: 62.5 nM - 16 mM Incubation Time: 1, 3 and 5 days Method: Cells are seeded at a density of 2× 10³ in 96-well plates and incubated overnight. Then Saracatinib (62.5 nM-16 mM) is added to the cells. After 1, 3 and 5 days, culture medium is removed followed by addition of 0.2 mL DMSO per well and continuous shaking of plates at 200 rotations per minute for 15min. Then IC50 is measured by MTT metho (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: CB17 mice are implanted with DU145 cells. Dosages: 25 mg/kg Administration: Orally administered daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	35 mg/mL warmed (64.57 mM)
	Ethanol	31 mg/mL (57.19 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Saracatinib (AZD0530) SDF

Molecular Weight	542.03
Formula	C₂₇H₃₂ClN₅O₅
CAS No.	379231-04-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04598919	Recruiting	Drug: Saracatinab\|Drug: Placebo	Idiopathic Pulmonary Fibrosis (IPF)	National Jewish Health\|Yale University\|Icahn School of Medicine at Mount Sinai\|AstraZeneca\|National Center for Advancing Translational Science (NCATS)	November 12 2020	Phase 1\|Phase 2
NCT04307953	Recruiting	Drug: AZD0530 Difumarate\|Drug: Matching placebo	Fibrodysplasia Ossificans Progressiva	VU University Medical Center\|Royal National Orthopaedic Hospital NHS Trust\|Klinikum Garmisch-Patenkirchen\|University of Oxford\|Brigham and Women''s Hospital\|AstraZeneca\|Innovative Medicines Initiative	August 5 2020	Phase 2
NCT02085603	Completed	Drug: Saracatinib\|Drug: Placebo	Cancer	Sheffield Teaching Hospitals NHS Foundation Trust\|AstraZeneca	March 2014	Phase 2
NCT01864655	Completed	Drug: saracatinib\|Drug: Placebo	Alzheimer''s Disease	Stephen M. Strittmatter\|Yale University	July 2013	Phase 1
NCT01000896	Withdrawn	Drug: AZD0530\|Drug: Carboplatin\|Drug: paclitaxel	Cancer\|Non Small Cell Lung Cancer\|Epithelial Ovarian Cancer	AstraZeneca	January 2010	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What is the half-life of Saracatinib?
Answer:
Based on the following paper, the half-life of Saracatinib in vivo is around 40hours and it reaches its peak lever around 2-4 hours after dosing: http://clincancerres.aacrjournals.org/content/16/19/4876.long

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Most Potent Src Inhibitor

Dasatinib : Src, IC50=0.8 nM.
FDA-approved Src Inhibitor

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
Newest Src Inhibitor

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
Classic Src Inhibitor

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Related Src Products

Dasatinib Monohydrate ^New

Dasatinib Monohydrate (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Bosutinib (SKI-606)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.
Dasatinib

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
KX2-391 (Tirbanibulin)

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
PP1

PP1 (AGL 1872, EI 275) is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
PP2

PP2 (AG 1879, AGL 1879), a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
WH-4-023

WH-4-023 (KIN001-112, KIN112, Dual LCK/SRC inhibitor) is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.

Choose Your Country or Region

By Signaling Pathways

By product type

Saracatinib (AZD0530)